Showing results (1021-1030 of 1,344) with videos related to

Sort By:
Pageof 135
The Pharmacogenomics Journal|February 18, 2025
The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening - a case-control studyLisanne E N Manson, Jacqueline D H Anholts, Jos J M Drabbels, et al.
The Pharmacogenomics Journal|October 2, 2025
An innovative model for pharmacogenomics critical results identification and interventionRyley Uber, Vanessa A Hayduk, Alison Flango, et al.
The Pharmacogenomics Journal|November 1, 2019
Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE StudyEva Clemens, Linda Broer, Thorsten Langer, et al.
The Pharmacogenomics Journal|December 10, 2019
An intronic FTO variant rs16952570 confers protection against thiopurine-induced myelotoxicities in multiethnic Asian IBD patientsSylvia Chen, Wei Zhi Tan, Natalia Sutiman, et al.
The Pharmacogenomics Journal|October 7, 2020
Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo populationFernando de Andrés, Catalina Altamirano-Tinoco, Ronald Ramírez-Roa, et al.
The Pharmacogenomics Journal|June 20, 2022
miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disordersEvangelia Eirini Tsermpini, Christina I Kalogirou, George C Kyriakopoulos, et al.
The Pharmacogenomics Journal|May 28, 2021
Gene expression signatures predict response to therapy with growth hormoneAdam Stevens, Philip Murray, Chiara De Leonibus, et al.
The Pharmacogenomics Journal|June 14, 2017
Genetic background influences susceptibility to chemotherapy-induced hematotoxicityD M Gatti, S N Weber, N C Goodwin, et al.
The Pharmacogenomics Journal|February 24, 2022
Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorderKatja Häkkinen, Johanna I Kiiski, Markku Lähteenvuo, et al.
The Pharmacogenomics Journal|February 1, 2022
Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenesJochen Fracowiak, Tatjana Huebner, Steffen Heß, et al.
Pageof 135